There are currently 26 active clinical trials seeking participants for Alzheimer's Disease research studies. The states with the highest number of trials for Alzheimer's Disease participants are Florida, California, New York and Arizona.
Wake Forest Alzheimer's Disease Clinical Core
NCT03140865
Recruiting
Efforts to find treatments for AD have yielded only modest benefits, likely because longstanding AD pathological processes induce irreversible neurological compromise. These processes begin years before the onset of clinical symptoms. This possibility has been incorporated into a model describing stages of AD development, articulated by the NIA/Alzheimer's Association preclinical workgroup of which the Co-Director of the Kulynych Alzheimer's Research Center, Dr. Suzanne Craft, was a member. Acco... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
04/23/2025
Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina
Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
Register for Updates
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
NCT06384573
Recruiting
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +5 locations
Conditions: Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
Register for Updates
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
NCT04396873
Recruiting
Background: About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation. Objective: To learn whether COX-1 and/or COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers. Eligibility: Adults age 18 years and older in good general he... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Dementia, Alzheimer's Disease, ALS, Parkinson's Disease, Mild Cognitive Impairment
Register for Updates
The Feasibility, Safety and Tolerability of VR-based Audiovisual Stimulation
NCT06234930
Recruiting
This is a single-blind, sham-controlled, clinical trial that aims to evaluate the safety, tolerability, and feasibility of delivering audiovisual stimulation via a Virtual Reality (VR) headset to people cognitively impaired due to Alzheimer's and cognitively unimpaired people.
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
02/18/2025
Locations: The Sequoias Portola Valley, Portola Valley, California +1 locations
Conditions: Healthy Aging, Alzheimer's Disease
Register for Updates
Retinal Imaging in Neurodegenerative Disease
NCT03233646
Recruiting
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Mild Cognitive Impairment, Multiple Sclerosis, Huntington Disease, Neuro-Degenerative Disease, Alzheimer's Disease, Parkinson's Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Normal Cognition
Register for Updates
A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors
NCT06411561
Recruiting
Up to 25% of intensive care unit (ICU) survivors experience cognitive impairment comparable in severity to mild Alzheimer's disease and related dementias after hospital discharge. Older ICU survivors (ages 60 and older) are at highest risk for delirium and subsequent cognitive impairment, which contribute to higher risk for cognitive decline related to Alzheimer's disease and related dementias. Sleep and activity are essential for recovery from critical illness, yet ICU survivors experience both... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
12/27/2024
Locations: University of Washington, Seattle, Washington
Conditions: Critical Illness, Delirium, Cognitive Impairment, Cognitive Decline, Alzheimer's Disease, Dementia, Circadian Dysrhythmia, Sleep Disturbance
Register for Updates
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
NCT05655195
Recruiting
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. The investigators developed a light and sound device for humans that stimulates the brain at 40Hz that can be used safely at home. For the... Read More
Gender:
ALL
Ages:
Between 65 years and 100 years
Trial Updated:
12/13/2024
Locations: Massachusetts Institute of Technology, Cambridge, Massachusetts
Conditions: Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer's Disease (Incl Subtypes), Alzheimer's, Alzheimer's Disease
Register for Updates
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)
NCT05658913
Recruiting
To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the phenotypic variability of Alzheimer's Disease and other related pathologies.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/13/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Alzheimer's Disease
Register for Updates
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
NCT05804383
Recruiting
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
07/29/2024
Locations: Yale University, New Haven, Connecticut +1 locations
Conditions: Alzheimer's Disease
Register for Updates
Music Therapy Experiences in Patients With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
NCT04666077
Recruiting
This study compares different music therapy (MT) experiences and their impact on memory and language in patients with Alzheimer's disease and Mild Cognitive Impairment. The 12-month study will assess the role of common experiences involving familiar music and other pleasant events (blinded control) to benefit cognition and measure the quality of life for people with Alzheimer's disease and Mild Cognitive Impairment. Following screening, all participants will meet with a licensed music therapis... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/26/2024
Locations: Louis Armstrong Center for Music and Medicine, Mount Sinai Beth Israel, New York, New York +1 locations
Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Register for Updates
New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study
NCT04426539
Recruiting
New IDEAS is an observational, open-label, longitudinal cohort study designed to address the requirements of the CED provisions of the NCD on beta-amyloid PET. Building on the initial Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study, New IDEAS will evaluate the association between amyloid PET and patient-centered outcomes in an expanded and more ethnoracially and clinically diverse group of Medicare participants presenting with cognitive impairment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Full list of Active Sites and Imaging Facilities, Philadelphia, Pennsylvania
Conditions: Alzheimer's Disease, Dementia, Mild Cognitive Impairment
Register for Updates
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
NCT05591027
Recruiting
This clinical trial is focused on determining whether biological signatures of target engagement by a Centella asiatica water extract product administered orally for 6 weeks can be measured in comparison to placebo. This study will also assess the safety and tolerability of the Centella asiatica water extract product.
Gender:
ALL
Ages:
Between 65 years and 85 years
Trial Updated:
04/05/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Register for Updates